---
document_datetime: 2024-12-05 17:22:59
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vantavo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vantavo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.2151218
conversion_datetime: 2025-12-28 10:39:32.461788
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## VANTAVO

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary        |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------|
| WS/2696              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of an updated RMP version 8.1 following the assessment outcome from procedure WS/2467 to | 31/10/2024                          | n/a                                         |                                  | not applicable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | of atypical femoral fracture from 'important potential risk' to 'important identified risk' and to extend the risk of 'atypical femoral fracture' to 'atypical fractures of long bones'. Further, the MAH took the opportunity to update the information in the RMP regarding important identified risks and missing information. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                 | reclassify the risk   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------|
| IG/1756   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                             | 16/07/2024 | 27/09/2024 | Annex II and PL |                       |
| WS/2699   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                    | 06/06/2024 | n/a        |                 | data                  |
| IG/1711/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/02/2024 | n/a        |                 |                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2467 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC in order to include information on the risk of 'atypical fractures of other bones' (than the femur), and update of section 4.8 to add 'atypical fractures of other bones' as a new ADR with frequency 'not known' and to include further information about the risk of 'atypical subtrochanteric and diaphyseal femoral fractures', based on post-marketing case reports and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes and to bring the product information in line with the latest QRD template and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 30/11/2023 | 27/09/2024 | SmPC, Labelling and PL | Although the pathophysiology is uncertain, consistent evidence from epidemiological studies suggests an increased risk of atypical subtrochanteric and diaphyseal femoral fractures with long-term bisphosphonate therapy for postmenopausal osteoporosis, particularly beyond three to five years of use. The absolute risk of atypical subtrochanteric and diaphyseal long bone fractures (bisphosphonate class adverse reaction) remains rare. Atypical fractures of other bones, such as the ulna and tibia have also been reported in patients receiving long-term treatment. As with atypical femoral fractures, these fractures occur after minimal, or no trauma and some patients experience prodromal pain prior to presenting with a completed fracture. In cases of ulna fracture, this may be associated with repetitive stress loading associated with the long-term use of walking aids. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                  | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                     |                                   |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------|
| IG/1634/G        | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 04/10/2023 | 27/09/2024 | Annex II and PL     |                                   |
| IG/1488          | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                             | 14/03/2022 | n/a        |                     |                                   |
| N/0039           | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                         | 27/10/2021 | 27/09/2024 | PL                  |                                   |
| PSUSA/79/20 2101 | Periodic Safety Update EU Single assessment - alendronic acid / colecalciferol, alendronic acid / calcium / colecalciferol                                                                                                                                                                                                                                                                                                                                                               | 02/09/2021 | n/a        |                     | PRAC Recommendation - maintenance |
| T/0037           | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/03/2021 | 13/04/2021 | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                              |            |            | PL                     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IG/1353 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                             | 11/02/2021 | n/a        |                        |
| N/0035  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 18/01/2021 | 13/04/2021 | PL                     |
| N/0034  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 11/12/2020 | 13/04/2021 | PL                     |
| WS/1857 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 04/09/2020 | 13/04/2021 | SmPC, Labelling and PL |
| IG/1266 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                             | 14/07/2020 | n/a        |                        |
| N/0031  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 28/11/2018 | 13/04/2021 | PL                     |
| T/0030  | Transfer of Marketing Authorisation                                                                                                                                                                                                          | 13/06/2018 | 09/07/2018 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| IG/0780          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 15/03/2017   | 15/02/2018   | SmPC, Annex II, Labelling and PL   |                                   |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------|
| IG/0764          | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                        | 31/01/2017   | n/a          |                                    |                                   |
| PSUSA/79/20 1601 | Periodic Safety Update EU Single assessment - alendronic acid / colecalciferol, alendronic acid / calcium / colecalciferol                                                                                                                   | 02/09/2016   | n/a          |                                    | PRAC Recommendation - maintenance |
| WS/0862          | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 01/04/2016   | 19/09/2016   | SmPC and PL                        |                                   |
| IG/0632          | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                | 03/12/2015   | n/a          |                                    |                                   |
| N/0024           | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 28/11/2015   | 19/09/2016   | Labelling and PL                   |                                   |
| WS/0752          | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                | 24/09/2015   | 19/09/2016   | SmPC and PL                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | inhibitors' as another example of a risk factor for ONJ. The Package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0516   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/01/2015 | n/a |
| WS/0657/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Type IB (B.I.a.2.e) - To introduce a minor change in the manufacturing process of the active substance to the restricted part of an Active Substance Master File. Type IA (B.I.b.1.c) - To introduce a specification parameter of a reagent used in the manufacturing process of the active substance Type IA (A.4) - To change the company name of the drug substance manufacturer from BASF Health & Nutrition A/S to BASF A/S Type IAIN (B.III.1.a.3) - To submit a new Ph. Eur. certificate of suitability from a new manufacturer for cholecalciferol. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an | 18/12/2014 | n/a |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0481 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                             | 29/09/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| R/0019  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/07/2014 | 18/09/2014 | SmPC, Annex II and PL | Based on the review of available information, the CHMP is of the opinion that the quality, safety and efficacy of Vantavo continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The product information has been updated to align with QRD templates, including paediatric information. The CHMP recommends that the renewal be granted with unlimited validity. |
| IG/0366 | C.I.8.a - Introduction of or changes to a summary of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/11/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0017    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 18/07/2013 | 18/09/2014 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IG/0182   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20/08/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| WS/0238   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the SmPC, Annex II, Labelling and Package leaflet to align with the Product Information approved in the context of the first renewal of ADROVANCE (EMEA/H/C/0759/R/013). In addition the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include linguistic corrections in Annex A. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 19/04/2012 | 25/05/2012 | SmPC, Annex II, Labelling and PL | This type IB variation concerns an update of the SmPC, Annex II, Labelling and Package leaflet (PL) to align them with the Product Information approved in the context of the first renewal of ADROVANCE; the changes resulted from implementation of the Agency QRD template version 8.0. In addition, the list of local representatives in the PL has been revised to amend contact details for the local representatives; linguistic corrections of Annex A were also accepted. This application was submitted following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. |
| WS/0212/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                                            | 19/04/2012 | 19/04/2012 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | variation B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling                                                                                                                                                                                                                                                                                |            |            |                        |                                                                |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------|
| IG/0112   | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                      | 11/10/2011 | n/a        |                        |                                                                |
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                            | 06/09/2011 | n/a        | PL                     |                                                                |
| A20/0005  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 19 October 2010, the opinion of the CHMP on measures necessary to ensure the safe use of the above mentioned medicinal product further to the CHMP review on the currently available data in relation to the incidence of atypical stress fractures and its impact on the risk-benefit balance. | 14/04/2011 | 29/06/2011 | SmPC, Annex II and PL  | Please refer to the Assessment Report: H-1180-RAR-A20- 0005-en |
| IG/0060/G | This was an application for a group of variations. B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information                                                                             | 27/04/2011 | n/a        | SmPC, Labelling and PL |                                                                |

<div style=\"page-break-after: always\"></div>

| WS/0095   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of SPC to re-structure section 4.8 (and corresponding section in the PL) in accordance with the current SPC Guideline and QRD guidance, as agreed during the assessment of the FOSAVANCE Renewal. In addition the MAH requested changes in Section 6 of the PL in the details of local representatives and a minor change in Annex II (deletion of DDPS version number). This application was submitted as a Type II variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-   | 17/02/2011   | 24/03/2011   | SmPC, Annex II and PL   | The information in section 4.8 of the SPC is restructured according to QRD guidance and the Guideline on Summary of Product Characteristics Rev.2 (September 2009). The previous separate tables for adverse reactions reported during clinical studies and/or post-marketing use with defined frequency, and adverse reactions reported during post-marketing experience with unknown frequency, have been consolidated into one single tabulated list of adverse reactions. Additionally, the frequency category for the adverse reactions that had been added to the label based on post-marketing data was re-assessed according to EU SmPC Guideline. In addition the MAH details of the local representatives in Section 6 of the PL were amended and the version number of the DDPS was deleted from Annex II .   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0040   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/01/2011   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| WS/0038   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21/10/2010   | 29/11/2010   | SmPC and PL             | This variation concerns an update of the SPC, further to a cumulative review by the MAH of spontaneous reports describing osteonecrosis of the jaw (ONJ), to add \"smoking\" as a risk factor for ONJ in section 4.4 of the SPC. The application was submitted as a Type II variation following a worksharing procedure according to Article 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                  |            |     |          | of Commission Regulation (EC) No 1234/2008. As the information about ONJ in the Product Information did not fully reflect the key messages regarding the risk minimisation measures for ONJ as identified in the Article 5(3) Referral on bisphosphonates and ONJ, additional wording fully reflecting those key messages were implemented in SPC section 4.4. The description of ONJ in SPC section 4.8 was shortened. The PL was amended accordingly, informing patients about the symptoms of ONJ and what action to take; advising on the need for patients to maintain good oral hygiene, to receive routine dental check ups and to report any oral symptoms such as dental mobility, pain or swelling; advising on the possible need for patients to have a dental check- up before starting treatment with the medicinal product. In addition, the PL section 2 was reformatted for FOSAVANCE/ADROVANCE/VANTAVO to make it consistent with FOSAMAX; the details of the Dutch local representative in Section 6 were amended; the ADROVANCE and VANTAVO annexes were harmonised with the annexes of Fosavance as agreed during the Fosavance   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0027/G | This was an application for a group of variations. C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 10/11/2010 | n/a | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0020 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                       | 14/09/2010 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| N/0004  | Update of the Italian and Spanish local representatives' details in the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                              | 21/05/2010 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IG/0003 | B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing                                                                                                                                                                                                                                                                        | 06/05/2010 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0002 | A.2.a: administrative change - Change in the (invented) name of the medicinal product for Centrally Authorised products. A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                               | 26/03/2010 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0001 | Update of section 4.4 'Special warnings and precautions for use' of the SPC to list Barrett's oesophagus as one of the oesophageal diseases requiring caution when alendronate therapy is administered, following a request from the CHMP. Update of section 2 of the PL accordingly. The marketing authorisation numbers and date of first authorisation were also included in the SPC and labelling. | 21/01/2010 | 15/03/2010 | SmPC, Labelling and PL | Following the assessment of the MAH's cumulative review of alendronate and oesophageal carcinoma, the CHMP concluded that Barrett's oesophagus is a potentially premalignant condition of the oesophagus and a significant marker for the development of oesophageal cancer. Although the data are currently inconclusive and further investigation is required, the possibility that alendronate use may be associated with an increased risk of oesophageal cancer can not be excluded. |

<div style=\"page-break-after: always\"></div>

| Update of Summary of Product Characteristics and Package Leaflet   | Therefore Barrett's oesophagus was included as a warning in section 4.4 of the SPC.   |
|--------------------------------------------------------------------|---------------------------------------------------------------------------------------|